Further data suggest that STAT3 inhibition would also contribute to reducing immunosuppression and increasing the immune infiltrate in the tumor, as well as reducing cancer-related inflammation with consequent clinical improvement in the patient: including a reduction in pain and fatigue and improvement in neurological function and quality of life. The gene discussed is STAT3; the disease is cancer.